TrialAutopsyBuilt by Jawad Momani (Pwnedl0l)

Autopsy report · NCT05643495

A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype

Cause of deathFunding or business Automatic label, confidence 0.5, unverified. How labels are made.
“Study drug dosing was permanently discontinued at the Sponsor's discretion based on frequency and nature of skin and subcutaneous tissue disorders.”

The sponsor’s own words in the registry.

Life of this trial

20222023202420252026Registered2022-11-29Started2023-02-23Stopped2024-08-19Results posted2025-09-08

Vital statistics

Status
Terminated
Phase
Phase 2
Sponsor
Vertex Pharmaceuticals Incorporated
Sponsor type
Industry
Conditions
Alpha-1 Antitrypsin Deficiency
Interventions
VX-864
Participants
14
Sites
13
Countries
Germany, Ireland, United Kingdom, United States

Trials that died the same way

Look deeper

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.